Authors' Reply to K. Langdon and Colleagues' Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy"

Affiliations

¹ Orthopaedic Department, Royal Children's Hospital, Parkville, VIC, Australia.
² Hugh Williamson Gait Laboratory, Royal Children's Hospital, Parkville, VIC, Australia.
³ Royal Children's Hospital, Parkville, VIC, Australia.
⁴ University of Melbourne, The Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia. kerr.graham@rch.org.au.

Comment

Iqbal Multani et al. Paediatr Drugs. 2019 Dec.

. 2019 Dec;21(6):497-499.

doi: 10.1007/s40272-019-00359-1.

¹ Orthopaedic Department, Royal Children's Hospital, Parkville, VIC, Australia.
² Hugh Williamson Gait Laboratory, Royal Children's Hospital, Parkville, VIC, Australia.
³ Royal Children's Hospital, Parkville, VIC, Australia.
⁴ University of Melbourne, The Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia. kerr.graham@rch.org.au.

No abstract available

Comment on

Botulinum Toxin in the Management of Children with Cerebral Palsy.
Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Multani I, et al. Paediatr Drugs. 2019 Aug;21(4):261-281. doi: 10.1007/s40272-019-00344-8. Paediatr Drugs. 2019. PMID: 31257556 Free PMC article. Review.
Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy".
Langdon K, Copeland L, Edwards P, Rodwell K, McLennan K, Carroll T, Bandaranayake S, Scheinberg A, Waugh MC, Burnett H, Wimalasundera N, Hennel S, Lim E, O'Flaherty S. Langdon K, et al. Paediatr Drugs. 2019 Dec;21(6):493-495. doi: 10.1007/s40272-019-00358-2. Paediatr Drugs. 2019. PMID: 31583614 No abstract available.